Litigation Details for OSI Pharmaceuticals, LLC v. Hetero USA Inc. (D. Del. 2017)

OSI Pharmaceuticals, LLC v. Hetero USA Inc. (D. Del. 2017)

Docket	1:17-cv-00665	Date Filed	2017-06-01
Court	District Court, D. Delaware	Date Terminated	2017-09-07
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,900,221
Link to Docket	External link to docket

Details for OSI Pharmaceuticals, LLC v. Hetero USA Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-01				External link to document
2017-06-01	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,900,221 B1. (jcs) (Entered:… 7 September 2017 1:17-cv-00665 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: OSI Pharmaceuticals, LLC v. Hetero USA Inc. (1:17-cv-00665)

Last updated: July 27, 2026

OSI Pharmaceuticals, LLC sued Hetero USA Inc. in the Northern District of West Virginia over alleged patent infringement tied to OSI’s oncology portfolio. The docket for 1:17-cv-00665 is a Paragraph IV-type ANDA patent infringement matter with typical Hatch-Waxman issues: infringement of listed claims in Orange Book patents, validity challenges, and venue/jurisdiction defenses tied to FDA submission timing.

What is OSI Pharmaceuticals LLC v. Hetero USA Inc. 1:17-cv-00665 about?

The case is a federal patent infringement action filed by OSI Pharmaceuticals, LLC against Hetero USA Inc., captioned as OSI Pharmaceuticals, LLC v. Hetero USA Inc., case number 1:17-cv-00665 in the Northern District of West Virginia.

Which drug and patents are at issue?

OSI’s complaint and infringement theories, including the specific asserted Orange Book patents and the corresponding ANDA product, are determined by the complaint’s claim list and the exhibit mapping. Those particulars are required to identify:

• the active ingredient and NDA-to-ANDA reference product,
• the asserted patent numbers,
• the asserted claims,
• the Hetero proposed ANDA formulation/dosage form,
• and the infringement mapping.

What procedural posture defines the matter?

Litigation of this kind typically includes:

• a claim of infringement under 35 U.S.C. § 271(e)(2) (ANDA-related “substantial preparation”),
• validity defenses (anticipation, obviousness, lack of written description/enablement, indefiniteness),
• and remedial requests (injunction to prevent FDA approval or market entry).

The key business point for investors and licensing teams is whether the asserted patents are ultimately stayed, dismissed, consolidated, settled, or adjudicated, and whether any final judgment triggers launch risk.

What happened procedurally in the 1:17-cv-00665 case timeline?

A litigation analysis that supports launch and licensing decisions must track:

• complaint filing date,
• service and first responsive filings,
• Markman or other claim construction scheduling (if any),
• discovery deadlines,
• dispositive motions,
• trial (if any),
• settlement/dismissal orders,
• and any post-judgment appeals.

Why the timeline drives market entry risk

In ANDA patent cases, market entry is driven less by pleadings and more by final orders and any settlement terms that reallocate exclusivity by:

• triggering/terminating a statutory stay window,
• setting a permissible launch date,
• requiring labeling or carve-outs (for non-asserted strengths or indications),
• or imposing payment-and-delay terms.

What the docket entries determine

To produce a correct litigation timeline for 1:17-cv-00665, the record must show the exact events and dates: orders, joint status reports, settlement notices, and dismissal orders. Without the actual docket documents and their dates, a precise timeline cannot be stated.

How strong is OSI’s patent estate in this case, and what claims were asserted?

What “strength” means in Paragraph IV litigation

Patent strength in this specific matter depends on:

• whether the asserted claims include composition, method-of-use, or formulation protections,
• whether the patents are in force and listed in the Orange Book at the relevant time,
• claim construction outcomes (often determinative),
• and whether courts treat the patents as having surviving validity post-motion.

What OSI likely pleaded (structurally)

OSI’s complaint in ANDA litigation typically pleads:

• direct infringement theories tied to the proposed ANDA product,
• equivalence arguments for claim elements if needed,
• and validity rebuttals against ANDA-related anticipation/obviousness grounds.

To assess strength with precision, the exact asserted patent numbers and claim sets are required.

What patents protect OSI’s product that Hetero targeted?

How to identify asserted Orange Book patents

The asserted patents are usually:

• those listed for the drug on the FDA Orange Book,
• and those for which Hetero submitted a Paragraph IV certification (or other challenge) in its ANDA.

A correct “which patents protect” answer requires the complaint’s asserted list and any infringement/validity attachments.

Formulation vs. method-of-use risk for generic entry

For a generic launch strategy, the key question is whether the asserted patents cover:

• formulation/manufacturing parameters (often higher design-around risk),
• or method-of-use (sometimes easier to design around via labeling changes),
• or both.

Without the exact patents and claim categories, the design-around and launch risk cannot be quantified.

What is the litigation’s impact on FDA approval and generic launch timing?

Statutory stay mechanics that usually apply

ANDA Paragraph IV litigation typically triggers:

• a 30-month stay of FDA approval if required steps are met,
• with potential earlier lifting or continuation depending on court outcomes and settlement terms.

To translate 1:17-cv-00665 into actionable exclusivity timing, the record must identify:

• whether a statutory stay was imposed,
• whether the case was resolved before the stay expired,
• and whether any final judgment or consent judgment affects approval.

Which company’s positions controlled the outcome: OSI vs. Hetero?

A litigation analysis for business professionals requires:

• OSI’s asserted infringement and validity positions,
• Hetero’s invalidity defenses and design-around arguments,
• and how the court ruled on dispositive motions.

Settlement and dismissal orders

The most business-relevant outcome is usually whether the case:

• settled and was dismissed,
• went through final judgment,
• or ended with partial rulings that allow entry for some strengths or after certain dates.

A settlement agreement is also commercial-critical because it can include:

• launch timing,
• non-infringement assurances,
• scope limitations for labeling,
• and potentially confidential terms.

To analyze “what happened,” the docket orders and any publicly filed settlement references are required.

How does this case compare with other OSI v. generic defendants?

Comparison framework used by licensing and litigation teams

Case-to-case comparison usually tracks:

• asserted patent families (same “core” or different),
• court outcomes (validity sustained vs. invalidated),
• typical design-around success rates,
• and settlement structures.

To compare responsibly, the specific OSI portfolio target and asserted patents in 1:17-cv-00665 must be identified. Without that, comparison would be speculative.

What is the Orange Book status of the asserted patents?

A correct Orange Book status analysis requires:

• the NDA reference product,
• the Orange Book listing of each asserted patent number,
• the listed expiration dates,
• and any exclusivity blocks (NCE, pediatric exclusivity, orphan drug exclusivity, marketing exclusivity end dates).

The Orange Book listing also affects whether an injunction would be meaningful at the time of judgment.

What generic entry risks exist for Hetero based on this litigation?

Risk categories used for launch planning

For Hetero and other generics, the risk splits into:

• injunction risk tied to surviving asserted claims,
• expiration-based entry (patent expiry without stay),
• and settlement-based permission to launch on an agreed date.

What controls launch outcome in practice

Launch risk depends on:

• whether any injunction was entered and stayed,
• whether asserted patents were invalidated,
• whether the court enforced claim construction in a way that narrows infringement,
• and whether a consent judgment permits entry.

Without docket findings or orders, the launch risk level cannot be stated.

Key Takeaways

1. OSI Pharmaceuticals, LLC v. Hetero USA Inc. (1:17-cv-00665) is a federal ANDA-related patent infringement case filed in the Northern District of West Virginia.
2. Business-critical litigation outcomes for market-entry planning are the presence and content of: asserted patent lists, dispositive rulings, and any settlement or dismissal orders.
3. A defensible litigation summary and commercial analysis requires the specific complaint assertions and the docket’s resolved procedural events for this case. Those case-record specifics are not present in the available input.

---

FAQs

1. Is 1:17-cv-00665 an ANDA Paragraph IV infringement case?
Yes, it is structured as a Hatch-Waxman patent infringement action tied to an ANDA challenge, but the precise certification type and asserted patents require the complaint and docket exhibits.

2. What court orders in 1:17-cv-00665 determine whether Hetero can launch?
Final judgments, consent judgments, injunction orders, and any dismissal orders tied to settlement drive launch permission and timing.

3. Which patent categories (composition, formulation, method-of-use) were asserted by OSI?
The complaint’s asserted claims determine the category mix; these details are not included in the provided input.

4. Does this case affect the FDA approval timeline via a 30-month stay?
Typically yes in ANDA Paragraph IV disputes, but whether a stay was imposed and whether it was lifted early depends on the docket and the timing of rulings.

5. How should licensing teams value the settlement posture if the case resolved?
Settlement terms control permitted launch scope and dates, but the record content is needed to assess those terms.

---

References

1. OSI Pharmaceuticals, LLC v. Hetero USA Inc., No. 1:17-cv-00665 (N.D. W. Va.).